

Mucopurulent Cervicitis (MPC)

DEFINITION	Inflammatory process with the presence of mucopurulent discharge from the cervix;
	etiology may be infection of ecto or endo cervix, neoplasia, inflammatory systemic
	process, or trauma/chemical irritation.
SUBJECTIVE	May include:
	1. No symptoms
	2. Risk factors for STDs
	3. Abnormal vaginal discharge
	4. Abnormal vaginal bleeding (i.e., post-coital, or intermenstrual)
	5. Dysuria or urinary frequency
	6. Sexual partner with symptoms of urethral discharge, dysuria, or history of NGU,
	epididymitis or prostatitis
OBJECTIVE	May include:
	Mucopurulent (green or yellow) discharge from/on the cervix
	2. Cervical erythema and/or contact bleeding
	3. Mild tenderness on compression of cervix
LABORATORY	May include:
	1. Vaginal/endocervical wet prep to rule out coexisting vaginal infection and assess
	polymorphonuclear leukocytes (WBCs)
	2. Test for chlamydia and gonococcal infection (although in most cases of MPC, neither
	organism can be isolated)
	3. HIV and syphilis testing
ASSESSMENT	Mucopurulent cervicitis
PLAN	1. First Recommended Treatment: Doxycycline 100 mg orally 2 times/day for 7 days
	2. Alternative Regimen: Azithromycin 1 g orally in a single dose.
	3. Treatment for chlamydia only, if the prevalence of N. gonorrhoeae is low but the likelihood of chlamydia is substantial (see Chlamydia Infection Protocol RD-1)
	4. Treatment for gonorrhea and chlamydia in client populations with high prevalence of
	both infections (see Gonococcal Infection Protocol RD-2)
	5. Await test results if the prevalence of both infections is low and if compliance with
	recommendation for a return visit is likely
	6. Clients who have MPC and also are infected with HIV should receive the same
	treatment regimen as those who are HIV negative
CLIENT	1. Provide client education handout(s) with review of symptoms, treatment options,
EDUCATION	and medication side effects
	2. Review safer sex education, if appropriate
	3. Recommend that client RTC PRN
CONSULT/ REFER	Clients whose symptoms do not resolve following treatment.

References:

- 1. Pp 53-55 https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf Pp 65-67.
- 2. Hatcher RA, Nelson A, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowel D, eds. Contraceptive Technology. 21 editions. New York, NY: Ayer Company Publishers, Inc., 2018. pp 612-613

Effective Date: September 2021 Last Reviewed: June 2021

Next Scheduled Review: June 2022